Grant: Operating Grant
McGill University
$383,741.00
Development and validation of MRI biomarkers for diagnosis and prognosis of prodromal Alzheimer's disease
EF 2010-11
Résumé
Alzheimer's currently affects approximately 0.5 million people in Canada, 5 million in North America, 25 million worldwide and will quadruple in prevalence by 2050 due to aging of the population. The social and financial costs are enormous. At present, it is estimated that the disease will affect 1 in 14 people that live to 80 years old. The aging baby-boomers are changing the population demographics, increasing the total numbers of people with AD. The good news is that the pharmaceutical industry is on the verge of a breakthrough in the treatment of Alzheimer's disease.
As in most diseases, early treatment of patients, before they have too much irreversible degeneration of brain tissue, is likely to be more effective. However, it is currently almost impossible to test drugs in patients with early Alzheimer's disease, due to the fact that only about 10-15% of patients with symptoms of mild cognitive impairment (MCI) suggestive of possible Alzheimer's disease will actually go on to develop Alzheimer's per year. This percentage is too low to allow for reasonably sized clinical trials, and it is unlikely that regulators would approve a drug for a population of patients, most of whom will never get the disease. We propose:
•to develop sophisticated image analysis tools to detect patterns of brain atrophy characteristic of Alzheimer's disease,
•to generate statistical models that will combine the image data with clinical data in order to predict which patients with MCI will rapidly go on to develop Alzheimer's disease.
The tools we develop will substantially facilitate the development of therapies for early Alzheimer's disease. They will make it feasible to perform drug trials in patients with MCI due to early Alzheimer's disease, and, looking forward, they will make it possible to select patients in the clinic for early treatment.
Programme
Operating Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
210241
Name
Collins Donald L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Medical Physics & Imaging
Projecttitle
Development and validation of MRI biomarkers for diagnosis and prognosis of prodromal Alzheimer's disease
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$383,741
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Biomarker; Diagnosis; Magnetic Resonance Imaging; Mild Cognitive Impairment; Prediction; Prodromal Alzheimer'S Disease
Abstract
Alzheimer's currently affects approximately 0.5 million people in Canada, 5 million in North America, 25 million worldwide and will quadruple in prevalence by 2050 due to aging of the population. The social and financial costs are enormous. At present, it is estimated that the disease will affect 1 in 14 people that live to 80 years old. The aging baby-boomers are changing the population demographics, increasing the total numbers of people with AD. The good news is that the pharmaceutical industry is on the verge of a breakthrough in the treatment of Alzheimer's disease.
As in most diseases, early treatment of patients, before they have too much irreversible degeneration of brain tissue, is likely to be more effective. However, it is currently almost impossible to test drugs in patients with early Alzheimer's disease, due to the fact that only about 10-15% of patients with symptoms of mild cognitive impairment (MCI) suggestive of possible Alzheimer's disease will actually go on to develop Alzheimer's per year. This percentage is too low to allow for reasonably sized clinical trials, and it is unlikely that regulators would approve a drug for a population of patients, most of whom will never get the disease. We propose:
•to develop sophisticated image analysis tools to detect patterns of brain atrophy characteristic of Alzheimer's disease,
•to generate statistical models that will combine the image data with clinical data in order to predict which patients with MCI will rapidly go on to develop Alzheimer's disease.
The tools we develop will substantially facilitate the development of therapies for early Alzheimer's disease. They will make it feasible to perform drug trials in patients with MCI due to early Alzheimer's disease, and, looking forward, they will make it possible to select patients in the clinic for early treatment.
Competitiondate
201009
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Collins, Donald L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $383,741~ $0~